journal article·2025-01

Neurotization of decellularized muscle graft increases de novo type I slow muscle fiber formation and large fiber size frequency

James T. Redden, David J. Cohen, Lucas C. Olson, Geetanjali Bendale, Jonathan E. Isaacs, Zvi Schwartz, Michael J. McClure

Acta Biomaterialia· Volume 191
Publisher page

Abstract

Volumetric muscle loss (VML) injuries are the result of extreme trauma from battlefield injuries, tumor ablations, and other physical traumas such as car crash injuries. The abrupt loss of muscle restricts the tissue's remaining regenerative capacity, leading to loss of satellite cells, peripheral nerve connections, and aberrant fibrosis. Prior research from our lab demonstrated that decellularized muscle matrix (DMM) supported regeneration of de novo fibers within the graft. The goal of this study was to determine whether DMM treated with a peripheral nerve using neurotization surgeries would enhance muscle regeneration and innervation. Forty-eight male Sprague Dawley rats were randomized and received a 1.5×1 cm defect treated with no treatment empty defect (ED), DMM, or autograft with a direct peroneal (antagonist) neurotization or tibial via end to side graft (agonist) neurotization. DMM grafts treated with neurotization utilizing either peroneal or tibial nerve axons increased fast twitch fibers within the grafted area compared to untreated DMM or ED. Additionally, the frequency distribution of myofiber size shifted toward a healthier morphology in the tibial nerve axon neurotized DMM compared to the uninjured medial head. Lastly, Nanostring gene results showed DMM treated with a neurotization shifted expression towards a more regenerative phenotype with some myogenic markers returning to sham levels. These data indicate that injured muscle treated with DMM and neurotization becomes pro-regenerative and can contribute to the functionalization of DMM. STATEMENT OF SIGNIFICANCE: Extremity soft tissue trauma like volumetric muscle loss (VML) can result in permanent loss of skeletal muscle mass, denervation, and ischemia posing a significant clinical challenge. VML injuries disrupt normal tissue architecture in addition to intramuscular axons which are critical elements in muscle function and regeneration. The overall objective of this study was to enhance axon growth into a VML injury treated with decellularized muscle matrix (DMM) using neurotization. DMM is an acellular biomaterial capable of regenerating skeletal muscle; however, without bona fide neuromuscular connections, functional gains are small. This study demonstrates that introducing motor axons into an acellular regenerative material using neurotization enhanced muscle regeneration and promoted slow twitch fiber formation.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Tissue Engineering and Regenerative Medicine · Electrospun Nanofibers in Biomedical Applications · Muscle Physiology and Disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (81)

Show source-provided references
1. Brain-derived neurotrophic factor regulates satellite cell differentiation and skeltal muscle regeneration10.1091/mbc.e10-02-0154 ↗
2. Nerve growth factor (NGF) influences differentiation and proliferation of myogenic cells in vitro via TrKA10.1016/S0736-5748(00)00041-1 ↗
3. Immunomodulation and biomaterials: key players to repair volumetric muscle loss10.3390/cells10082016 ↗
4. Current methodologies for inducing aligned myofibers in tissue constructs for skeletal muscle tissue regeneration10.1089/wound.2024.0111 ↗
5. Aligned collagen sponges with tunable pore size for skeletal muscle tissue regeneration10.3390/jfb14110533 ↗
6. The role of semaphorin3A in myogenic regeneration and the formation of functional neuromuscular junctions on new fibres10.1111/brv.12286 ↗
7. Volumetric muscle loss leads to permanent disability following extremity trauma10.1682/JRRD.2014.07.0165 ↗
8. Vascularized and innervated skeletal muscle tissue engineering10.1002/adhm.201900626 ↗
9. Blast injuries10.1056/NEJMra042083 ↗
10. Soft tissue management of war wounds to the foot and ankle10.1016/j.fcl.2009.10.006 ↗
11. Electrodiagnostic evaluation of individuals implanted with extracellular matrix for the treatment of volumetric muscle injury: case series10.2522/ptj.20150133 ↗
12. Secondary denervation is a chronic pathophysiologic sequela of volumetric muscle loss10.1152/japplphysiol.00049.2021 ↗
13. Differential expression of neural cell adhesion molecule (NCAM) after tenotomy in rabbit skeletal muscle10.1016/S0736-0266(01)00095-X ↗
14. Fibre type specific expression of Leu19-antigen and N-CAM in skeletal muscle in various stages after experimental denervation10.1007/BF01608336 ↗
15. Direct neurotization of severely damaged denervated muscles
16. RNU (Foxn1 (RNU)-Nude) rats demonstrate an improved ability to regenerate muscle in a volumetric muscle injury compared to sprague dawley rats10.3390/bioengineering8010012 ↗
17. Decellularized muscle supports new muscle fibers and improves function following volumetric injury10.1089/ten.tea.2017.0386 ↗
18. Combined regenerative rehabilitation improves recovery following volumetric muscle loss injury in a rat model10.1002/jbm.b.35438 ↗
19. Direct extrusion of multifascicle prevascularized human skeletal muscle for volumetric muscle loss surgery
20. Novel muscle-derived extracellular matrix hydrogel promotes angiogenesis and neurogenesis in volumetric muscle loss10.1016/j.matbio.2024.02.001 ↗
21. A transitional extracellular matrix instructs cell behavior during muscle regeneration10.1016/j.ydbio.2010.05.007 ↗
22. Laminin 521 maintains differentiation potential of mouse and human satellite cell-derived myoblasts during long-term culture expansion10.1186/s13395-016-0116-4 ↗
23. Laminin-111 improves muscle repair in a mouse model of merosin-deficient congenital muscular dystrophy10.1093/hmg/ddt428 ↗
24. Biomaterials for the development of peripheral nerve guidance conduits10.1089/ten.teb.2011.0240 ↗
25. The influence of fibronectin and laminin during Schwann cell migration and peripheral nerve regeneration through silicon chambers10.1007/BF01246356 ↗
26. Matrix-bound nanovesicles within ECM bioscaffolds10.1126/sciadv.1600502 ↗
27. Decellularized human skeletal muscle as biologic scaffold for reconstructive surgery10.3390/ijms160714808 ↗
28. M. Erb, Quantitative determination of muscle fiber diameter (minimal Feret's diameter) and percentage of centralized nuclei, Treat NMD Wellstone Muscular Dystrophy Center, 2008, pp. 1-14.
29. Presynaptic NCAM is required for motor neurons to functionally expand their peripheral field of innervation in partially denervated muscles10.1523/JNEUROSCI.0697-14.2014 ↗
30. Adaptation of nicotinic acetylcholine receptor, myogenin, and MRF4 gene expression to long-term muscle denervation10.1083/jcb.131.5.1341 ↗
31. Gene expression of myogenic regulatory factors, nicotinic acetylcholine receptor subunits, and GAP-43 in skeletal muscle following denervation in a rat model10.1002/jor.20414 ↗
32. In situ forming biomaterials as muscle void fillers for the provisional treatment of volumetric muscle loss injuries
33. Reverse end-to-side (Supercharging) nerve transfer: conceptualization, validation, and translation10.1177/1558944720988076 ↗
34. Reconstruction of posterior compartment of lower extremity using a functional latissimus dorsi free flap: A case report10.1002/micr.22443 ↗
35. Reinnervated free muscle transplantation for extremity reconstruction10.1097/00006534-199304001-00021 ↗
36. Free tissue transfer for the treatment of facial paralysis10.1055/s-2008-1075834 ↗
37. Free functioning muscle transfer for lower extremity posttraumatic composite structure and functional defect10.1097/01.prs.0000260595.85557.41 ↗
38. Functioning muscle transplantation after wide excision of sarcomas in the extremity
39. Functional regeneration of the murine neuromuscular synapse relies on long-lasting morphological adaptations10.1186/s12915-022-01358-4 ↗
40. On the effect of muscle activity on the end-plate membrane in denervated mouse muscle10.1113/jphysiol.1989.sp017546 ↗
41. Turnover of acetylcholine receptors in skeletal muscle10.1101/SQB.1976.040.01.025 ↗
42. Direct muscle neurotization recovers gastrocnemius muscle function10.1055/s-2007-1006655 ↗
43. Engineered skeletal muscle units for repair of volumetric muscle loss in the tibialis anterior muscle of a rat10.1089/ten.tea.2014.0060 ↗
44. Innervation of an engineered muscle graft for reconstruction of muscle defects10.1111/ajt.14957 ↗
45. R. Whitaker, S. Sung, T. Tylek, G. Risser, E. O'Brien, P.E. Chua, T. Li, R.J. Petrie, L. Han, B. Binder-Markey, K.L. Spiller, Effects of injury size on local and systemic immune cell dynamics in volumetric muscle loss, bioRxiv (2024).10.1101/2024.08.26.609702 ↗
46. Differential recovery of neuromuscular function after nerve/muscle injury induced by crude venom from Notechis scutatus, cardiotoxin from Naja atra and bupivacaine treatments in mice10.1016/j.neures.2007.04.001 ↗
47. Reverse end-to-side neurotization in a regenerating nerve10.1055/s-0028-1088230 ↗
48. Reverse end-to-side neurotization10.1055/s-2005-862780 ↗
49. Asynchronous inflammation and myogenic cell migration limit muscle tissue regeneration mediated by a cellular scaffolds
50. Naturally derived and synthetic scaffolds for skeletal muscle reconstruction10.1016/j.addr.2014.08.011 ↗
51. Differential utilization of beta-tubulin isotypes in differentiating neurites10.1083/jcb.109.2.663 ↗
52. Distinct alpha- and beta-tubulin isotypes are required for the positioning, differentiation and survival of neurons: new support for the 'multi-tubulin' hypothesis10.1042/BSR20100025 ↗
53. The role of microtubules in the immune system and as potential targets for gut-based immunotherapy10.1016/j.molimm.2019.04.014 ↗
54. Expression of the low-affinity NGF receptor during human muscle development, regeneration, and in tissue culture10.1002/mus.880170304 ↗
55. BDNF is expressed in skeletal muscle satellite cells and inhibits myogenic differentiation10.1523/JNEUROSCI.5398-05.2006 ↗
56. The low-affinity receptor for neurotrophins p75NTR plays a key role for satellite cell function in muscle repair acting via RhoA10.1091/mbc.e09-01-0012 ↗
57. Nerve growth factor expression in human dystrophic muscles10.1002/mus.10332 ↗
58. Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy10.1523/JNEUROSCI.20-07-02589.2000 ↗
59. Cross-talk between motor neurons and myotubes via endogenously secreted neural and muscular growth factors10.14814/phy2.14791 ↗
60. Early myosin switching induced by nerve activity in regenerating slow skeletal muscle10.1247/csf.22.147 ↗
61. Both myoblast lineage and innervation determine fiber type and are required for expression of the slow myosin heavy chain 2 gene10.1006/dbio.1997.8619 ↗
62. Innervation-dependent and fiber type-specific transcriptional regulation of the slow myosin heavy chain 2 promoter in avian skeletal muscle fibers10.1002/dvdy.20137 ↗
63. "Fast" and "slow" muscle fibres in hindlimb muscles of adult rats regenerate from intrinsically different satellite cells10.1113/jphysiol.2004.073684 ↗
64. Autologous minced muscle grafts: a tissue engineering therapy for the volumetric loss of skeletal muscle10.1152/ajpcell.00189.2013 ↗
65. Unwavering pathobiology of volumetric muscle loss injury10.1038/s41598-017-13306-2 ↗
66. Pax7 is required for the specification of myogenic satellite cells10.1016/S0092-8674(00)00066-0 ↗
67. Transcriptional dominance of Pax7 in adult myogenesis is due to high-affinity recognition of homeodomain motifs10.1016/j.devcel.2012.03.014 ↗
68. Function of the myogenic regulatory factors Myf5, MyoD, Myogenin and MRF4 in skeletal muscle, satellite cells and regenerative myogenesis10.1016/j.semcdb.2017.11.011 ↗
69. The regenerating skeletal muscle niche drives satellite cell return to quiescence10.1016/j.isci.2022.104444 ↗
70. Impaired skeletal muscle hypertrophy signaling and amino acid deprivation response in Apoe knockout mice with an unhealthy lipoprotein distribution10.1038/s41598-021-96000-8 ↗
71. APP interacts with LRP4 and agrin to coordinate the development of the neuromuscular junction in mice10.7554/eLife.00220 ↗
72. RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass10.1172/JCI169317 ↗
73. Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy10.1186/s40478-018-0533-1 ↗
74. Human skeletal muscle possesses an epigenetic memory of hypertrophy10.1038/s41598-018-20287-3 ↗
75. Targeting PLA2G16, a lipid metabolism gene, by Ginsenoside Compound K to suppress the malignant progression of colorectal cancer10.1016/j.jare.2021.06.009 ↗
76. PLA2G16 is a mutant p53/KLF5 transcriptional target and promotes glycolysis of pancreatic cancer10.1111/jcmm.15832 ↗
77. PLA2G16 promotes osteosarcoma metastasis and drug resistance via the MAPK pathway10.18632/oncotarget.7694 ↗
78. An inhibitor of phospholipase A2 group IIA modulates adipocyte signaling and protects against diet-induced metabolic syndrome in rats10.2337/db11-1179 ↗
79. New role for ceramide in hypoxia and insulin resistance10.3748/wjg.v26.i18.2177 ↗
80. Vasoconstriction in exercising skeletal muscles: a potential role for neuropeptide Y?10.1152/ajpheart.00071.2004 ↗
81. Sympathomimetics regulate neuromuscular junction transmission through TRPV1, P/Q- and N-type Ca10.1016/j.mcn.2019.01.007 ↗